immunocore global commercialstage biotechnology based oxfordshire researches develops biological drugs using soluble tcell receptor technology immunocore founded spinout medigene ag acquired avidex core technology spun oxford university bent jakobsen avidex july immunocore announced completion initial million private financing round europes largest ever financing round private life sciences fidelity management research company woodford investment management malin corporation eli lilly company rtw investments participated fundraise along unnamed investors existing september bill melinda gates foundation announced million investment immunocore accelerate development immunocore immtav immtab march immunocore announced closing million series b private financing january immunocore announced closing million series c immunocore went public february closing announced february cell receptors tcrs molecules found surface lymphocytes cells play various roles immune system tcrs often cited aiding recognising foreign antigens presented cells infected viruses intracellular bacteria immunocore developed line biologic medicines combining engineered cancerrecognising soluble tcrs immune activating complexes direct immune system kill cancer cells drugs commonly referred immunemobilising monoclonal tcrs cancer immtac tebentafusp soluble bispecific cell november immunocore announced phase data readout tebentafusp field jan us fda approved tebentafusptebn adult patients unresectable metastatic uveal immunocores pipeline programs include immtac candidate phase partnered genentech treatment solid tumors expressing immtac candidate also phase studies solid tumors expressing prame earlier programs include candidates treatment hepatitis b virus hbv human immunodeficiency virus hiv sir john bell serves immunocores chairman board bahija jallal chief executive officer director httpsenwikipediaorgwikiimmunocore